Skip to main content

Simon Schwartz Navarro

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services

Simon Schwartz Navarro

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Currently acting as Strategy director of biobanking and bioresources at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 40, with more that 115 high impact publications and 17 transferred patents. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM.

Projects

Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease

IP: -
Collaborators: Ibane Abasolo Olaortua, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua
Funding agency: EUROPEAN COMMISSION
Funding: 266300.8
Reference: SMART4FABRY_H2020NMBP2016
Duration: 01/01/2017 - 31/12/2020

(Nano) systems with active targeting to sensitize colorectal cancer stem cells to anti-tumoral treatment Target4Cancer

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre, Joaquin Seras Franzoso, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 143385
Reference: AC15/00092
Duration: 01/01/2016 - 30/09/2019

NoCanTher: Nanomedicine Upscaling for Early Clinical Phases of Multimodal Cancer Therapy

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua, Joaquin Seras Franzoso, Tamara Del Rio Higueras, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez
Funding agency: EUROPEAN COMMISSION
Funding: 630633.55
Reference: NOCANTHER_H2020NMP2015
Duration: 01/04/2016 - 30/09/2021

Grup de direccionament i alliberament farmacològic

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua, Montse Capella Tomás, José García Arumí, Laura García Latorre, José Raul Herance Camacho
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 1394
Duration: 01/01/2014 - 31/12/2016

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Marta Palau Requena

Marta Palau Requena

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
González Sánchez Alejandra

González Sánchez Alejandra

Predoctoral researcher
Microbiology
Read more
Rodrigo Maluje Juri

Rodrigo Maluje Juri

Predoctoral researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Marta Antonio Martín

Marta Antonio Martín

Predoctoral researcher
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.